Clinical Trial Search

Primary: Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma — 37; 55 Participants — p=<0.0001

Primary: mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit — 15; 8 participants

Primary: Adverse Events — 3; 0; 1; 0 Participants

Primary: Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea — 3; 4; 0; 4 Participants

Primary: The Primary Objective is to Assess the Safety of 13C Urea Administered by Inhalation. — 0; 0 adverse events

Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants

Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…

Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053

Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants

Primary: Assess Microbiological Failure of Recommended Azithromycin and Doxycycline Regimens in Uncomplicated Chlamydia Trachomatis Infection in a Setting Where Repeat Exposure…

Primary: Post-operative Urinary Tract Infection — 19; 20 Participants

Primary: The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections — 0.80; 1.00 proportion of participants — p=1.000

Primary: Number of Participants Who Have Cystitis — 4; 4 Participants

Primary: Proportion of Asymptomatic Bacteriuria Treated With Antibiotics and Urinary Tract Infection Treated With Antibiotics — 31; 25 Participants

Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…

Primary: Change in Vaginal Microbiota — 2.75 change in percent relative abundance

Primary: Favorable Clinical Outcomes (FCl) — 170; 132 Participants

Primary: Incidence of Urinary Tract Infection — 7; 13 participants

Primary: Incidence of Post-operative UTI Following the Placement of Sub-urethral Sling for the Treatment of Stress Urinary Incontinence — 13; 24 participants

Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants

Primary: Number of Subjects With Combined Clinical and Microbiologic Response — 70 Participants

Primary: Clinical Sensitivity and Specificity for Microorganism Detection as Compared to Routine Microbiology and Other Reference Methods Including PCR and Sequencing — 91.4…

Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001

Primary: Microbiological Response Assessment Profile — 58; 63 Participants

Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003

Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants

Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001

Primary: Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy — 111; 122 Participants

Primary: UTI Incidence as Described Below, Over the 16 Week Study Period Following Randomization, in the LACTIN-V Treatment Group (Group A) as Compared to the Placebo Group…

Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants